Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease


Current drugs used in the treatment of Parkinson's disease (PD), for example, L-DOPA and dopamine agonists, are very effective at reversing the motor symptoms of the disease. However, they do little to combat the underlying degeneration of dopaminergic neurones in the substantia nigra pars compacta (SNc) and their long-term use is associated with the… (More)
DOI: 10.1111/j.1476-5381.2010.00882.x

3 Figures and Tables


  • Presentations referencing similar topics